TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
*
Home
Press release
Feb 07, 2019 09:00 JST
Source:
Lubrizol
Lubrizol LifeSciences to Showcase New Medical Device Applications Lab at MDM West 2019
CLEVELAND, Ohio, Feb 07, 2019 - (ACN Newswire) - The Lubrizol Corporation announces its LifeSciences business will feature a new medical device applications lab. LifeSciences has invested significantly to expand its global development and manufacturing facilities, and the latest investment is a new state-of-the-art medical device applications lab in Brecksville, Ohio. This lab features applications testing, small-scale compounding as well as injection molding for long-term implantables. The 1,800-square foot facility will also focus on accelerated R&D, from polymers to device scale up and testing in a short period of time.
The medical device applications lab is yet another substantial piece of LifeSciences' full-service capabilities. These capabilities and more will be on display at the MD&M West Exposition (Booth #2401), February 5-7. Lubrizol LifeSciences is a preferred medical device development partner, helping customers from concept to commercialization by offering polymer customization, drug-eluting device development and contract manufacturing services. At MD&M, LifeSciences will also highlight a strong presence in the interventional catheter, long-term implant and drug-eluting device markets. In addition, LifeSciences will unveil new dexamethasone-loaded polymers designed to minimize inflammation and help ensure the success of implantable medical devices.
"The new applications lab is another commitment to healthcare companies looking for a full-service development partner. We continue to invest in the right areas to provide valuable offerings where our customers are experiencing the most growth," states Uwe Winzen, general manager, Lubrizol LifeSciences. "When customers partner with Lubrizol LifeSciences, they benefit from working with us at every stage in their development process."
Offering more than 90 years of science and technology experience, Lubrizol is uniquely structured to partner with medical device manufacturers by providing proactive innovation, speed to market, and expertise for the most demanding projects. From materials to development and manufacturing, or anything in between - Lubrizol LifeSciences is equipped to support the needs of customers worldwide.
About Lubrizol LifeSciences
Lubrizol LifeSciences is a preferred Contract Development and Manufacturing Organization (CDMO) partner for complex pharmaceuticals and high-end medical devices providing differentiated polymers and excipients, along with state-of-the-art design, development and manufacturing services to the healthcare industry.
About The Lubrizol Corporation
The Lubrizol Corporation, a Berkshire Hathaway company, is a market-driven global company that combines complex, specialty chemicals to optimize the quality, performance and value of customers' products while reducing their environmental impact. It is a leader at combining market insights with chemistry and application capabilities to deliver valuable solutions to customers in the global transportation, industrial and consumer markets. Lubrizol improves lives by acting as an essential partner in our customers' success, delivering efficiency, reliability or wellness to their end users. Technologies include lubricant additives for engine oils, driveline and other transportation-related fluids, industrial lubricants, as well as additives for gasoline and diesel fuel. In addition, Lubrizol makes ingredients and additives for home care, personal care and skin care products and specialty materials encompassing polymer and coatings technologies, along with polymer-based pharmaceutical and medical device solutions.
With headquarters in Wickliffe, Ohio, Lubrizol owns and operates manufacturing facilities in 17 countries, as well as sales and technical offices around the world. Founded in 1928, Lubrizol has approximately 8,700 employees worldwide. Revenues for 2017 were $6.3 billion. For more information, visit Lubrizol.com.
Media Contact
Ben Patti
(216) 447-5827
Benjamin.patti@lubrizol.com
www.lubrizol.com/LifeSciences
###
This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Lubrizol via Globenewswire
Source: Lubrizol
Copyright ©2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Related Press Release
Lubrizol Announces Global Collaboration with Corbion
June 18 2019 16:30 JST
Particle Sciences Expands Controlled Substance Capabilities with Approval of DEA Schedule I Registration
May 29 2019 10:00 JST
Lubrizol to Present at the 29th CIMAC World Congress 2019
May 29 2019 10:00 JST
Lubrizol Aims at Circular Economy with TPU Solutions for Footwear
May 17 2019 08:00 JST
Lubrizol Announces Collaboration with Ultimaker's Material Alliance Program
May 15 2019 09:00 JST
Ground Breaking Ceremony at New Lubrizol LUCANT Plant
April 30 2019 08:00 JST
Lubrizol's Diamond Dispersions Business Wins Queen's Award for International Trade
April 23 2019 23:00 JST
Lubrizol to Feature New Bio TPU Grades for 3D Printing and Molded Parts at Plastteknik Fair 2019
April 18 2019 07:30 JST
Lubrizol is Ready for ILSAC GF-6 - Announcing Lubrizol(R) PV1510 Additive Technology for the GF-6 Specification
April 16 2019 07:00 JST
Lubrizol Showcases Renewable-Sourced Estane(R) 3D ECO TPU for 3D Printing at RAPID + TCT 2019
April 12 2019 20:30 JST
More Press release >>
Latest Press Release
Sharp Launches A2 Size ePoster Color Electronic Paper Display
Jun 19, 2025 12:08 JST
Fujitsu unveils AI-powered presentation technology, enabling automated multilingual and customizable presentations
Jun 19, 2025 10:25 JST
ULVAC Continues Participation in "Lab-in-Fab" Project to Advance Piezoelectric MEMS Technology, Now Entering a New Phase
Jun 19, 2025 09:30 JST
NEC and Chugai Pharmaceutical use AI to potentially enhance cancer treatment
Jun 18, 2025 13:40 JST
Fujitsu awarded contract to design next-generation flagship supercomputer FugakuNEXT
Jun 18, 2025 11:35 JST
Honda Celebrates 60th Anniversary of First F1 Victory with Special Events Program
Jun 17, 2025 17:45 JST
MHI Receives Order to Supply 5 Models of Pumps, a Total of 34 Units, for Sizewell C Unit 1 and 2 in the UK from Trillium Flow Technologies
Jun 17, 2025 17:10 JST
Honda Teams to Compete in 2025 FIM Endurance World Championship "Coca-Cola" Suzuka 8 Hours Endurance Road Race 46th Tournament
Jun 16, 2025 16:37 JST
Fujitsu unveils Millimeter-Wave Monitoring System for enhanced safety and privacy in care facilities
Jun 16, 2025 16:20 JST
Tat Hong Equipment Service Co., Ltd. Announces 2024/25 Annual Results
Jun 13, 2025 22:49 JST
Yee Hop Holdings (1662.HK) Subsidiary APEL Launches Microfactory in Collaboration with HKPC
Jun 13, 2025 21:38 JST
Jacobson Pharma Announces FY2025 Annual Results
Jun 13, 2025 20:16 JST
TRENDE Announces Strategic Capital and Business Alliance with Tokyu Land
Jun 13, 2025 13:00 JST
Supercomputer Fugaku retains first place worldwide in Graph500 rankings
Jun 10, 2025 19:47 JST
International Consortium Rolls Out Major EV Battery Swapping Initiative in Tokyo
Jun 06, 2025 16:42 JST
TANAKA PRECIOUS METAL TECHNOLOGIES Receives 2025 Technology Award from Catalyst Manufacturers Association, Japan, for Development and Practical Application of Electrode Catalysts for PEM Water Electrolysis
Jun 06, 2025 11:00 JST
Fujitsu unveils Technology and Service Vision 2025: People-AI collaboration for a net positive future
Jun 06, 2025 10:44 JST
Alpha Growth plc: Alpha Alternative Assets Fund Update ("AAAF")
Jun 04, 2025 15:00 JST
MHI Thermal Systems Receives A' Design Awards
Jun 04, 2025 14:10 JST
Orange completes successful trial of Fujitsu 1FINITY optical transport solution
Jun 04, 2025 12:58 JST
More Latest Release >>